Literature DB >> 10446388

Evidence for IRF-1-dependent gene expression deficiency in interferon unresponsive HepG2 cells.

M Tnani1, B A Bayard.   

Abstract

Induction of the antiproliferative and antiviral state by IFNs (type I and II) is dramatically impaired in HepG2 cells. We show here that RNase L, IDO, GBP-2 and iNOS genes normally expressed as a secondary response to IFN are no longer inducible in HepG2 cells, while induction of primary response genes (IRF-1, PKR, p48-ISGF3gamma, 2-5AS, 6-16 and p56-(trp)tRNA) are unaffected. On the basis of previous data implicating transcription factor IRF-1 in the induction of some IFN-induced genes, we tested the effects of transfecting an IRF-1 oligonucleotide antisense in HeLa cells and found specifically impaired IFN induction of secondary response genes (RNase L, IDO and GBP-2). This raised the possibility that IRF-1 was defective in HepG2 cells. However, some molecular and biochemical analyses reveal that IRF-1 is induced normally by IFNs and retains its normal size, cellular location, phosphorylation status and ability to bind the IDO promoter in vitro. Therefore, we conclude that although the primary response pathway is fully functional, some aspects of the secondary pathway involving IRF-1 (but not IRF-1 itself) are defective in HepG2 cells. It may be possible that the promoter region of these deficient HepG2-genes requires an unidentified transcription factor in addition to de novo IRF-1, which could be elicited by a cooperative activator.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446388     DOI: 10.1016/s0167-4889(99)00089-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases.

Authors:  Clara Lubeseder-Martellato; Eric Guenzi; Anita Jörg; Kristin Töpolt; Elisabeth Naschberger; Elisabeth Kremmer; Christian Zietz; Erwin Tschachler; Peter Hutzler; Martin Schwemmle; Kathrin Matzen; Thomas Grimm; Barbara Ensoli; Michael Stürzl
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation.

Authors:  Philipp Tropberger; Alexandre Mercier; Margaret Robinson; Weidong Zhong; Don E Ganem; Meghan Holdorf
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

3.  Role of interferon-stimulated gene factor 3gamma and beta interferon in HLA class I enhancement in synovial fibroblasts upon infection with Chlamydia trachomatis.

Authors:  Jürgen Rödel; Heinz Vogelsang; Katrin Prager; Matthias Hartmann; Karl-Hermann Schmidt; Eberhard Straube
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.

Authors:  Thananya Jinato; Natthaya Chuaypen; Witthaya Poomipak; Kesmanee Praianantathavorn; Jarika Makkoch; Rattanaporn Kiatbumrung; Kanisa Jampoka; Pisit Tangkijvanich; Sunchai Payungporn
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

5.  Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.

Authors:  Amir Shlomai; Robert E Schwartz; Vyas Ramanan; Ankit Bhatta; Ype P de Jong; Sangeeta N Bhatia; Charles M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

6.  Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels.

Authors:  Sherri L Christian; Thaddeus W Collier; Dong Zu; Maria Licursi; Chris M Hough; Kensuke Hirasawa
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

7.  An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.

Authors:  Yutaka Furutani; Mariko Toguchi; Yumi Shiozaki-Sato; Xian-Yang Qin; Etsuko Ebisui; Shoko Higuchi; Masayuki Sudoh; Harukazu Suzuki; Nobuaki Takahashi; Koichi Watashi; Takaji Wakita; Hideaki Kakeya; Soichi Kojima
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

8.  Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes.

Authors:  Yuichi Akahori; Hiroki Kato; Takashi Fujita; Kohji Moriishi; Yasuhito Tanaka; Koichi Watashi; Michio Imamura; Kazuaki Chayama; Takaji Wakita; Makoto Hijikata
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

9.  Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus.

Authors:  Shun Kaneko; Sei Kakinuma; Yasuhiro Asahina; Akihide Kamiya; Masato Miyoshi; Tomoyuki Tsunoda; Sayuri Nitta; Yu Asano; Hiroko Nagata; Satoshi Otani; Fukiko Kawai-Kitahata; Miyako Murakawa; Yasuhiro Itsui; Mina Nakagawa; Seishin Azuma; Hiromitsu Nakauchi; Hironori Nishitsuji; Saneyuki Ujino; Kunitada Shimotohno; Masashi Iwamoto; Koichi Watashi; Takaji Wakita; Mamoru Watanabe
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

Review 10.  Advances in HBV infection and replication systems in vitro.

Authors:  Ruirui Xu; Pingping Hu; Yuwen Li; Anran Tian; Jun Li; Chuanlong Zhu
Journal:  Virol J       Date:  2021-05-29       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.